Search

Your search keyword '"Shan, Jenny"' showing total 182 results

Search Constraints

Start Over You searched for: Author "Shan, Jenny" Remove constraint Author: "Shan, Jenny"
182 results on '"Shan, Jenny"'

Search Results

10. Peripherally administered desacetyl [alpha]-MSH and [alpha]-MSH both influence postnatal rat growth and associated rat hypothalamic protein expression

11. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: A randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor

19. Multi-Faceted Rasch Measurement and Bias Patterns in EFL Writing Performance Assessment

20. Peripherally administered desacetyl α-MSH and α-MSH both influence postnatal rat growth and associated rat hypothalamic protein expression

21. α-MSH and Desacetyl-α-MSH Signaling through Melanocortin Receptors

22. alpha-MSH and desacetyl-alpha-MSH signaling through melanocortin receptors

25. EUTOS Score Is Not Predictive for Survival and Outcome in Patients (pts) with Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKIs) At MD Anderson Cancer Center (MDACC),

26. Improved Survival in Chronic Myeloid Leukemia (CML) Since the Introductin of Imatinib Therapy - A Single Institution Historical Experience

28. Impact of Treatment End Point Definitions on Perceived Differences in Long-Term Outcome With Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia

29. The Achievement of a 3-Month Complete Cytogenetic Response (3-mo CCyR) to Second Generation (2nd) Tyrosine Kinase Inhibitors (TKI) Post Imatinib Failure Is the Only Predictive Factor for Event-Free (EFS) and Overall Survival (OS)

30. The Achievement of An Early Complete Cytogenetic Response (CCyR) Is A Major Determinant for Outcome In Patients (pts) with Early Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs).

31. Incidence of Secondary Neoplasms In Patients with Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid (ATRA) with Chemotherapy or with Arsenic Trioxide (ATO).

35. Efficacy of Nilotinib in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP).

36. Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure.

38. Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy

39. Prognostic Significance of Prior Best Response to Imatinib in Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs).

44. Delayed Achievement of Molecular Responses Is Associated with Increased Risk of Progression among Patients (pts) with Chronic Myelogenous Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib (IM).

47. Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate

50. MULTI-FACETED RASCH MEASUREMENT AND BIAS PATTERNS IN EFL WRITING PERFORMANCE ASSESSMENT.

Catalog

Books, media, physical & digital resources